In Boston, Massachusetts, on June 1, 2026, Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on revolutionizing autoimmune disease treatment, revealed that the Compensation Committee of the Board of Directors issued stock options for 61,050 shares of Vor Bio’s common stock and restricted stock units (RSUs) for 12,900 shares of Vor Bio’s common stock to 10 newly onboarded employees. These incentives were provided under the Nasdaq Listing Rule 5635(c)(4) and granted via the Vor Biopharma Inc. 2023 Inducement Plan as enticements for joining the company.